Infliximab infusion (Remicade) for Crohns Disease at Addenbrookes NHS hospital

Infliximab, marketed as Remicade, is a biologic therapy that works by blocking a protein called tumor necrosis factor-alpha (TNF-alpha), reducing inflammation and suppressing the overactive immune response associated with Crohn's Disease.

Infliximab is given as an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein at Addenbrookes NHS Hospital under supervised medical conditions.

An Infliximab infusion typically takes between 2 to 3 hours. Patients will be monitored during the infusion for any adverse reactions.

The initial treatment usually involves infusions at weeks 0, 2, and 6, followed by maintenance infusions every 8 weeks, although the schedule may vary based on individual patient needs.

During your first infusion, medical staff will check your vital signs and begin the intravenous administration of Infliximab. You'll be observed throughout to ensure you don't experience any adverse reactions.

Common side effects include infusion-related reactions such as headache, dizziness, rash, and fever. Serious side effects can occur as well, so it's important to report any unusual symptoms to your healthcare team.

It's important to discuss your complete medical history with your doctor at Addenbrookes, as some conditions may affect the suitability of Infliximab or require additional precautions.

Tell your healthcare provider about all medications you are taking, as Infliximab may interact with other drugs. This includes over-the-counter drugs and supplements.

There are no special preparations needed, but it is advised to eat a light meal beforehand and wear comfortable clothing. Bring any medications you may need and plan for a way to get home safely.

Yes, Infliximab is covered by the NHS for the treatment of Crohn's Disease when prescribed by a specialist at a hospital like Addenbrookes.

Many patients continue their normal activities while on Infliximab, although you should avoid heavy lifting or stressful activities on the day of the infusion. Discuss your specific circumstances with your healthcare provider.

Contact your healthcare provider immediately if you experience any adverse effects or symptoms after receiving an Infliximab infusion, especially if they are severe or persistent.

Improvement in symptoms can be seen as early as a few weeks after starting treatment. Regular follow-ups and assessments will help determine the effectiveness of the therapy for your condition.

Discuss your plans and any concerns about pregnancy with your healthcare provider, as they will provide guidance based on your specific situation and latest clinical guidelines.

For more information, you can contact your specialist team at Addenbrookes Hospital or the patient support services available through the NHS.